VRCA — Verrica Pharmaceuticals Cashflow Statement
0.000.00%
- $45.22m
- $43.93m
- $7.57m
Annual cashflow statement for Verrica Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
Depreciation | |||||
Non-Cash Items | 10.6 | 7.56 | 6.92 | 17.7 | 12.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.64 | -0.535 | -1.8 | 9.86 | 2.03 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -30.2 | -27.6 | -18.6 | -38.6 | -60.9 |
Capital Expenditures | -1.47 | -0.883 | -0.302 | -0.362 | -0.027 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -2.11 | -0.115 | 54.3 | 0 | 0.008 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -3.58 | -0.998 | 54 | -0.362 | -0.019 |
Financing Cash Flow Items | 0.319 | 0 | -0.017 | -0.176 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 35.2 | 33.6 | -16.9 | 74.2 | 37.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.45 | 5.07 | 18.5 | 35.3 | -23.2 |